Mescaline is a psychedelic from peyote and San Pedro cacti; microdosing means repeatedly administering amounts too small to change perception, aiming to support mood and focus. No controlled study has tested such doses in people. Reported gains come mainly from users who knew they received it, and studies of related psychedelics point to expectation. Higher doses affect blood pressure, heart rate, and digestion. The case for benefit is speculative. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Resting blood pressure | Below 120/80 mmHg | Mescaline raises blood pressure at 200 mg and above |
| Resting heart rate | 50–70 beats per minute | Heart rate rises with dose |
| Electrocardiogram | Normal rhythm and conduction | Screens for arrhythmia (irregular heartbeat) before stimulant-like exposure |
| Echocardiogram (heart ultrasound) | No more than trivial valve leakage | Baseline for the unresolved serotonin 2B valve concern |
| Estimated glomerular filtration rate | 90 mL/min/1.73 m² or higher | About half of a dose is excreted unchanged by the kidneys |
| Depression symptom score | 0–4 (minimal) | Tracks the claimed mood benefit against baseline |
| Anxiety symptom score | 0–4 (minimal) | Anxiety is a reported adverse effect |
| Cognitive control task (for example, a Stroop test) | No established target; track change from own baseline | Pooled microdosing studies show a small loss of cognitive control |
| Inflammation marker (high-sensitivity C-reactive protein) | Below 1.0 mg/L | Tests the speculative anti-inflammatory claim |
Cadence: Baseline before a first dose; blood pressure and heart rate at the first dose, weekly for the first month, then monthly during courses; mood, anxiety, and cognitive scores at baseline, week 4, and course end, then every 3–6 months; echocardiogram and kidney function every 12 months with continued use